The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Why miltefosine—a life-saving drug for leishmaniasis—is unavailable to people who need it the most
Open accessAbstract
Miltefosine, the only oral drug approved for the treatment of leishmaniasis—a parasitic disease transmitted by sandflies—is considered as a success story of research and development (R&D) by a public-private partnership (PPP). It epitomises the multiple market failures faced by a neglected disease drug: patients with low ability to pay, neglect by authorities and uncertain market size. Originally developed as an anticancer agent in the 1990s, the drug was registered in India in 2002 to treat the fatal visceral leishmaniasis. At the time, miltefosine was considered a breakthrough in the treatment, making it feasible to eliminate a regional disease. Today, access to miltefosine remains far from secure. The initial PPP agreement which includes access to the public sector is not enforced. The reality on the ground has been challenging: shortages due to inefficient supply chains, and use of a substandard product which led to a high number of treatment failures and deaths. Miltefosine received orphan drug status in the USA; when it was registered there in 2014, a priority review voucher (PRV) was awarded. The PRV, meant to facilitate drug development for neglected disease, was subsequently sold to another company for US$125 million without, to date, any apparent impact on drug access. At the heart of these concerns are questions on how to protect societal benefit of a drug developed with public investment, while clinicians worldwide struggle with its lack of affordability, limited availability and sustainability of access. This article analyses the reasons behind the postregistration access failure of miltefosine and provides the lessons learnt.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leishmaniasis Worldwide and Global Estimates of Its Incidence
Alvar, J., Vélez, I. D., Bern, C., Herrero, M., Desjeux, P., Cano, J., Jannin, J., Boer, M. D., & the WHO Leishmaniasis Control Team (2012) · PLoS ONE · doi:10.1371/journal.pone.0035671 · Cited by 5,141
Registering New Drugs for Low-Income Countries: The African Challenge
Moran, M., Strub-Wourgaft, N., Guzman, J., Boulet, P., Wu, L., & Pecoul, B. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000411 · Cited by 44
Cited by
Chagas Disease in the United States: a Public Health Approach
Bern, C., Messenger, L. A., Whitman, J. D., & Maguire, J. H. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00023-19 · Cited by 282
Metadata
- Authors
- Sunyoto, T., Potet, J., & Boelaert, M.
- Venue
- BMJ Global Health
- Publisher
- BMJ
- Published
- 2018-05
- Volume
- 3
- Issue
- 3
- Pages
- e000709
- ISSN
- 2059-7908 (ISSN-L)
- OpenAlex
- W2802132488
- Cited by
- 160
- References
- 2
- FWCI
- 28.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Why miltefosine—a life-saving drug for leishmaniasis—is unavailable to people who need it the most. https://app.cochat.ai/papers/10.1136/bmjgh-2018-000709
- The paper
- Sunyoto, T., Potet, J., & Boelaert, M. (2018). Why miltefosine—a life-saving drug for leishmaniasis—is unavailable to people who need it the most. BMJ Global Health. https://doi.org/10.1136/bmjgh-2018-000709
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.